ZA200702364B - Lercanidipine salts - Google Patents
Lercanidipine saltsInfo
- Publication number
- ZA200702364B ZA200702364B ZA200702364A ZA200702364A ZA200702364B ZA 200702364 B ZA200702364 B ZA 200702364B ZA 200702364 A ZA200702364 A ZA 200702364A ZA 200702364 A ZA200702364 A ZA 200702364A ZA 200702364 B ZA200702364 B ZA 200702364B
- Authority
- ZA
- South Africa
- Prior art keywords
- lercanidipine salts
- lercanidipine
- salts
- Prior art date
Links
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical class COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60414904P | 2004-08-24 | 2004-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200702364B true ZA200702364B (en) | 2008-09-25 |
Family
ID=35159792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200702364A ZA200702364B (en) | 2004-08-24 | 2007-03-22 | Lercanidipine salts |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7683179B2 (https=) |
| EP (1) | EP1799644B1 (https=) |
| JP (1) | JP2008510754A (https=) |
| KR (1) | KR20070045351A (https=) |
| CN (1) | CN101048379A (https=) |
| AR (1) | AR050467A1 (https=) |
| AU (1) | AU2005276619B2 (https=) |
| BR (1) | BRPI0514606A (https=) |
| CA (1) | CA2575078A1 (https=) |
| EA (1) | EA011773B1 (https=) |
| ES (1) | ES2462921T3 (https=) |
| IL (1) | IL180905A0 (https=) |
| MX (1) | MX2007002141A (https=) |
| NO (1) | NO20071515L (https=) |
| NZ (1) | NZ553127A (https=) |
| PE (1) | PE20060629A1 (https=) |
| TW (1) | TW200613275A (https=) |
| WO (1) | WO2006021397A1 (https=) |
| ZA (1) | ZA200702364B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100926247B1 (ko) * | 2001-02-24 | 2009-11-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법 |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| AR052918A1 (es) * | 2005-02-25 | 2007-04-11 | Recordati Ireland Ltd | Clorhidrato de lercanidipina amorfo |
| AR053023A1 (es) * | 2005-02-25 | 2007-04-18 | Recordati Ireland Ltd | Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| KR101452915B1 (ko) | 2006-05-04 | 2014-10-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| CA2654230C (en) | 2006-06-12 | 2012-09-11 | Novartis Ag | Process for making a lactate salt of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
| WO2008040367A1 (en) * | 2006-08-01 | 2008-04-10 | Union Quimico-Farmaceutica S.A. | Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof |
| US20080175872A1 (en) * | 2006-09-28 | 2008-07-24 | Osmotica Corp. | Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid |
| ES2306595B1 (es) * | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
| IN2009DN05509A (https=) * | 2007-03-14 | 2010-04-30 | Teva Pharma | |
| WO2009017813A1 (en) * | 2007-08-02 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | O-desmethyl venlafaxine saccharinate |
| WO2009070311A2 (en) | 2007-11-26 | 2009-06-04 | Teva Pharmaceutical Industries Ltd. | Crystal forms of o-desmethylvenlafaxine fumarate |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| US20100105743A1 (en) * | 2008-08-01 | 2010-04-29 | Gopal Krishna | Pharmaceutical compositions and methods for stabilizing the same |
| PL2320740T3 (pl) * | 2008-08-01 | 2014-09-30 | The Medicines Co | Kompozycje farmaceutyczne klewidypiny oraz sposoby ich wytwarzania z niskim stężeniem zanieczyszczeń |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| CA2736421A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| WO2011121452A2 (en) * | 2010-03-29 | 2011-10-06 | Pliva Hrvatska D.O.O. | Crystal forms of o-desmethylvenlafaxine fumarate |
| CA3070513C (en) | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| EP4524132A4 (en) * | 2022-05-10 | 2026-04-22 | Myrodia Therapeutics Co Ltd | 2-METHYL-2-THIAZOLINE SALT |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8403866D0 (en) | 1984-02-14 | 1984-03-21 | Recordati Chem Pharm | Diphenylalkylaminoalkyl esters |
| US5696139A (en) | 1995-05-12 | 1997-12-09 | Recordati S.A., Chemical And Pharmaceutical Company | Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure |
| IT1275532B (it) * | 1995-07-14 | 1997-08-07 | Recordati Chem Pharm | Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa |
| US5767136A (en) | 1995-05-12 | 1998-06-16 | Recordati, S.A. Chemical And Pharmaceutical Company | 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls |
| IT1301759B1 (it) * | 1998-06-19 | 2000-07-07 | Nicox Sa | Sali nitrati di farmaci antiipertensivi |
| US20030069285A1 (en) | 2001-08-06 | 2003-04-10 | Recordati Ireland Limited | Novel solvate and crystalline forms of lercanidipine hydrochloride |
| US6852737B2 (en) | 2001-08-06 | 2005-02-08 | Recordati Ireland Limited | Crude and crystalline forms of lercanidipine hydrochloride |
| US6699892B2 (en) * | 2002-06-04 | 2004-03-02 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Pharmaceutically acceptable salt of amlodipine and method of preparing the same |
| JP2006504800A (ja) * | 2002-10-16 | 2006-02-09 | レコーダチ アイルランド リミテッド | リシノプリル／レルカニジピンの組み合わせ治療 |
| US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
-
2005
- 2005-08-19 TW TW094128384A patent/TW200613275A/zh unknown
- 2005-08-22 CA CA002575078A patent/CA2575078A1/en not_active Abandoned
- 2005-08-22 AU AU2005276619A patent/AU2005276619B2/en not_active Ceased
- 2005-08-22 WO PCT/EP2005/009043 patent/WO2006021397A1/en not_active Ceased
- 2005-08-22 NZ NZ553127A patent/NZ553127A/xx not_active IP Right Cessation
- 2005-08-22 CN CNA2005800284676A patent/CN101048379A/zh active Pending
- 2005-08-22 JP JP2007528715A patent/JP2008510754A/ja not_active Abandoned
- 2005-08-22 PE PE2005000963A patent/PE20060629A1/es not_active Application Discontinuation
- 2005-08-22 AR ARP050103516A patent/AR050467A1/es not_active Application Discontinuation
- 2005-08-22 EA EA200700492A patent/EA011773B1/ru not_active IP Right Cessation
- 2005-08-22 ES ES05776228.8T patent/ES2462921T3/es not_active Expired - Lifetime
- 2005-08-22 MX MX2007002141A patent/MX2007002141A/es not_active Application Discontinuation
- 2005-08-22 EP EP05776228.8A patent/EP1799644B1/en not_active Expired - Lifetime
- 2005-08-22 BR BRPI0514606-2A patent/BRPI0514606A/pt not_active IP Right Cessation
- 2005-08-22 KR KR1020077006715A patent/KR20070045351A/ko not_active Withdrawn
- 2005-08-24 US US11/211,769 patent/US7683179B2/en not_active Expired - Fee Related
-
2007
- 2007-01-23 IL IL180905A patent/IL180905A0/en unknown
- 2007-03-22 ZA ZA200702364A patent/ZA200702364B/xx unknown
- 2007-03-23 NO NO20071515A patent/NO20071515L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL180905A0 (en) | 2007-07-04 |
| EA200700492A1 (ru) | 2007-08-31 |
| AU2005276619B2 (en) | 2009-04-30 |
| KR20070045351A (ko) | 2007-05-02 |
| NO20071515L (no) | 2007-05-22 |
| EA011773B1 (ru) | 2009-06-30 |
| EP1799644A1 (en) | 2007-06-27 |
| TW200613275A (en) | 2006-05-01 |
| US7683179B2 (en) | 2010-03-23 |
| MX2007002141A (es) | 2007-04-27 |
| CA2575078A1 (en) | 2006-03-02 |
| PE20060629A1 (es) | 2006-08-11 |
| WO2006021397A1 (en) | 2006-03-02 |
| ES2462921T3 (es) | 2014-05-26 |
| AR050467A1 (es) | 2006-10-25 |
| CN101048379A (zh) | 2007-10-03 |
| NZ553127A (en) | 2009-07-31 |
| BRPI0514606A (pt) | 2008-06-17 |
| US20060047125A1 (en) | 2006-03-02 |
| WO2006021397A8 (en) | 2006-04-27 |
| AU2005276619A1 (en) | 2006-03-02 |
| EP1799644B1 (en) | 2014-02-12 |
| JP2008510754A (ja) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200702364B (en) | Lercanidipine salts | |
| AP2006003810A0 (en) | 4-Phenylamino-quinazolin-6-yl-amides | |
| DE502005007040D1 (en) | Laryngoskop | |
| ZA200708127B (en) | Amorphous lercanidipine hydrochloride | |
| DE502005007456D1 (en) | Nanoemulsionen | |
| DE502005003298D1 (en) | Ls | |
| GB0425544D0 (en) | Barrier | |
| DE502004004685D1 (en) | Giessmaschine | |
| IL181938A0 (en) | Lercanidipine capsules | |
| ZA200708126B (en) | Lercanidipine free base | |
| GB0409898D0 (en) | A composition | |
| DE502004004917D1 (en) | Multiaxialkomplex | |
| GB0413563D0 (en) | Shaped pulse | |
| DE502005006813D1 (en) | Common-rail-injektor | |
| DE502005004945D1 (en) | Auto-splice-system | |
| HK1102961A (en) | Lercanidipine salts | |
| GB0425955D0 (en) | Salt form | |
| AU2909P (en) | DT23 Dianella tasmanica | |
| GB0413172D0 (en) | Stop | |
| ZA200703549B (en) | Lercanidipine capsules | |
| AU156488S (en) | A faceguard | |
| AU158015S (en) | A sailplane | |
| ZAA200500628S (en) | A botttle | |
| GB0410585D0 (en) | Barrier | |
| GB0410591D0 (en) | Barrier |